Trade Regeneron Pharmaceuticals, Inc. (Extended hours) - REGN CFD
Add to favourite- Summary
- Historical Data
| Spread | 1.65 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.023512% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.00129% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 0.01 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 690.45 |
| Open | 693.96 |
| 1-Year Change | -26.68% |
| Day's Range | 690.95 - 703.04 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Feb 21, 2025 | 700.35 | 8.40 | 1.21% | 691.95 | 703.86 | 690.95 |
| Feb 20, 2025 | 690.45 | 6.89 | 1.01% | 683.56 | 702.30 | 683.56 |
| Feb 19, 2025 | 683.56 | 3.05 | 0.45% | 680.51 | 688.18 | 674.08 |
| Feb 18, 2025 | 679.21 | 5.75 | 0.85% | 673.46 | 689.61 | 673.46 |
| Feb 14, 2025 | 672.39 | 9.44 | 1.42% | 662.95 | 683.14 | 662.95 |
| Feb 13, 2025 | 672.05 | 9.57 | 1.44% | 662.48 | 676.95 | 659.95 |
| Feb 12, 2025 | 662.40 | -3.06 | -0.46% | 665.46 | 671.23 | 655.81 |
| Feb 11, 2025 | 665.46 | -24.49 | -3.55% | 689.95 | 691.95 | 664.07 |
| Feb 10, 2025 | 689.95 | -20.30 | -2.86% | 710.25 | 718.95 | 688.50 |
| Feb 7, 2025 | 708.96 | -17.39 | -2.39% | 726.35 | 730.55 | 704.95 |
| Feb 6, 2025 | 726.35 | 11.45 | 1.60% | 714.90 | 733.73 | 709.05 |
| Feb 5, 2025 | 714.90 | 17.88 | 2.57% | 697.02 | 727.43 | 688.93 |
| Feb 4, 2025 | 697.02 | 31.57 | 4.74% | 665.45 | 709.16 | 636.95 |
| Feb 3, 2025 | 664.95 | -3.88 | -0.58% | 668.83 | 673.02 | 663.32 |
| Jan 31, 2025 | 671.95 | -8.01 | -1.18% | 679.96 | 689.95 | 671.40 |
| Jan 30, 2025 | 679.95 | -5.00 | -0.73% | 684.95 | 689.22 | 674.05 |
| Jan 29, 2025 | 690.26 | 4.81 | 0.70% | 685.45 | 697.51 | 681.95 |
| Jan 28, 2025 | 676.95 | -6.02 | -0.88% | 682.97 | 689.56 | 674.95 |
| Jan 27, 2025 | 682.97 | 21.43 | 3.24% | 661.54 | 697.66 | 661.54 |
| Jan 24, 2025 | 675.95 | -13.00 | -1.89% | 688.95 | 695.65 | 674.97 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
Regeneron Company profile
Regeneron Pharmaceuticals, Inc., a biopharmaceutical company, discovers, invents, develops, manufactures, and commercializes medicines for the treatment of serious medical conditions worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema (DME); myopic choroidal neovascularization; and diabetic retinopathy in patients with DME, as well as macular edema following retinal vein occlusion, including macular edema following central retinal vein occlusion and macular edema following branch retinal vein occlusion. It also provides Dupixent injection to treat adult patients with moderate-to-severe atopic dermatitis; Praluent injection, an adjunct to diet and maximally tolerated statin therapy for the treatment of adults with heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease; and Kevzara solution for subcutaneous injection to treat rheumatoid arthritis in adults. In addition, the company offers ARCALYST injection for cryopyrin-associated periodic syndromes; and ZALTRAP, an injection for intravenous infusion, which is used in combination with 5-fluorouracil, leucovorin, and irinotecan for the treatment of metastatic colorectal cancer. Further, it develops EYLEA, a trap-based clinical product that is in Phase III study for the treatment of neovascular glaucoma; and Dupixent, Praluent, Kevzara, Suptavumab, Cemiplimab, Fasinumab, Evinacumab, Nesvacumab/aflibercept, Trevogrumab, REGN1908-1909, REGN1979, REGN3470-3471-3479, REGN2477, REGN3500, REGN3767, and REGN3918, which are antibody-based clinical programs under various stages of development. The company has collaboration and license agreements with Sanofi, Bayer, Mitsubishi Tanabe Pharma, Teva, Intellia Therapeutics, Adicet Bio, Decibel Therapeutics, Astellas, Alnylam Pharmaceuticals, Inc., and others. Regeneron Pharmaceuticals, Inc. was founded in 1988 and is headquartered in Tarrytown, New York.| Industry: | Bio Therapeutic Drugs |
777 Old Saw Mill River Road
TARRYTOWN
NEW YORK 10591
US
News
Microsoft Stock Price Forecast for 2025 and beyond: Third party price target
We assess the likely level of the Microsoft stock price in 5 years, and possible drivers behind the stock’s past performance. Read on...
18:29, 7 February 2025
Ripple XRP price prediction: Third-party price target
Discover the ripple (XRP) price predictions for 2025 and beyond, with analyst price targets and CFDs trading strategies on Capital.com
15:29, 6 February 2025
Apple (AAPL) stock price forecast: third-party price target
We looked at the forecasts for Apple stock in 10 years to see where the price would likely be at that point and the challenges the company could face. Read more.
11:22, 6 February 2025
FARTCOIN price prediction: Third-party price target
Read our FARTCOIN price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:18, 29 January 2025
MELANIA coin ($MELANIA) price prediction: Third party price target
Read our MELANIA crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts.
11:33, 22 January 2025
TRUMP coin ($TRUMP) price prediction: third-party price target
Read our TRUMP crypto price prediction for 2025 and beyond, with insights from third-party analysts and market experts
10:52, 22 January 2025
Ethereum price prediction: Third party data round up
What is the outlook for ETH as a long-term investment?
16:37, 7 January 2025People also watch
Still looking for a broker you can trust?
Join the 690,000+ traders worldwide that chose to trade with Capital.com